Details of the Drug

General Information of Drug (ID: DMA16BR)

Drug Name

Vorapaxar

Synonyms

Vorapaxar; 618385-01-6; Zontivity; SCH-530348; SCH530348; UNII-ZCE93644N2; CHEMBL493982; CHEBI:82702; ZCE93644N2; MK-5348; ethyl ((1R,3aR,4aR,6R,8aR,9S,9aS)-9-((E)-2-(5-(3-fluorophenyl)pyridin-2-yl)vinyl)-1-methyl-3-oxododecahydronaphtho[2,3-c]furan-6-yl)carbamate; Ethyl [(1r,3ar,4ar,6r,8ar,9s,9as)-9-{(E)-2-[5-(3-Fluorophenyl)pyridin-2-Yl]ethenyl}-1-Methyl-3-Oxododecahydronaphtho[2,3-C]furan-6-Yl]carbamate; Vorapaxar [USAN:INN]; Carbamic acid, [(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(1E)-2-[5-(3-fluorophenyl)-2- pyridinyl]etheny

Indication

Disease Entry	ICD 11	Status	REF
Myocardial infarction	BA41-BA43	Approved	[1], [2], [3]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

492.6

Topological Polar Surface Area (xlogp)

5.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [4]
Bioavailability: The bioavailability of drug is 100% [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.34 mL/min/kg [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 3 - 4 days [5]
Metabolism: The drug is metabolized via the CYP3A4 and CYP 2J2 [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.01% [5]
Vd: The volume of distribution (Vd) of drug is 424 L [6]

Chemical Identifiers

Formula: C29H33FN2O4
IUPAC Name: ethyl N-[(1R,3aR,4aR,6R,8aR,9S,9aS)-9-[(E)-2-[5-(3-fluorophenyl)pyridin-2-yl]ethenyl]-1-methyl-3-oxo-3a,4,4a,5,6,7,8,8a,9,9a-decahydro-1H-benzo[f][2]benzofuran-6-yl]carbamate
Canonical SMILES: CCOC(=O)N[C@@H]1CC[C@@H]2[C@@H](C1)C[C@@H]3[C@H]([C@H]2/C=C/C4=NC=C(C=C4)C5=CC(=CC=C5)F)[C@H](OC3=O)C
InChI: InChI=1S/C29H33FN2O4/c1-3-35-29(34)32-23-10-11-24-20(14-23)15-26-27(17(2)36-28(26)33)25(24)12-9-22-8-7-19(16-31-22)18-5-4-6-21(30)13-18/h4-9,12-13,16-17,20,23-27H,3,10-11,14-15H2,1-2H3,(H,32,34)/b12-9+/t17-,20+,23-,24-,25+,26-,27+/m1/s1
InChIKey: ZBGXUVOIWDMMJE-QHNZEKIYSA-N

Cross-matching ID

PubChem CID: 10077130
ChEBI ID: CHEBI:82702
CAS Number: 618385-01-6
DrugBank ID: DB09030
TTD ID: D0VA0I
INTEDE ID: DR1708
ACDINA ID: D00732

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proteinase activated receptor 1 (F2R)	TTL935N	PAR1_HUMAN	Antagonist	[7], [8], [9]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[10]
Cytochrome P450 2J2 (CYP2J2)_{Main DME}	DERSX5P	CP2J2_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Myocardial infarction

ICD Disease Classification

BA41-BA43

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proteinase activated receptor 1 (F2R)	DTT	F2R	4.89E-02	-0.32	-0.77
Cytochrome P450 2J2 (CYP2J2)	DME	CYP2J2	2.00E-01	-1.92E-02	-9.96E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	5.08E-01	-8.08E-02	-5.30E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Vorapaxar (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Arn-509	DMT81LZ	Major	Increased metabolism of Vorapaxar caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[35]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Vorapaxar caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[36]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Vorapaxar caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[37]
Tucatinib	DMBESUA	Major	Decreased metabolism of Vorapaxar caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[36]
Intedanib	DMSTA36	Moderate	Increased risk of bleeding by the combination of Vorapaxar and Intedanib.	Colorectal cancer [2B91]	[38]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Vorapaxar caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[39]
Vortioxetine	DM6F1PU	Moderate	Increased risk of bleeding by the combination of Vorapaxar and Vortioxetine.	Depression [6A70-6A7Z]	[40]
Apigenin	DMI3491	Minor	Increased risk of bleeding by the combination of Vorapaxar and Apigenin.	Discovery agent [N.A.]	[41]
Tazemetostat	DMWP1BH	Major	Increased risk of bleeding by the combination of Vorapaxar and Tazemetostat.	Follicular lymphoma [2A80]	[35]
Avapritinib	DMK2GZX	Major	Increased risk of bleeding by the combination of Vorapaxar and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[42]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Vorapaxar caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[36]
Ceritinib	DMB920Z	Major	Decreased metabolism of Vorapaxar caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[36]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Vorapaxar caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[43]
Idelalisib	DM602WT	Major	Decreased metabolism of Vorapaxar caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[36]
Acalabrutinib	DM7GCVW	Major	Increased risk of bleeding by the combination of Vorapaxar and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[44]
Ibrutinib	DMHZCPO	Major	Increased risk of bleeding by the combination of Vorapaxar and Ibrutinib.	Mature B-cell lymphoma [2A85]	[45]
Fedratinib	DM4ZBK6	Major	Increased risk of bleeding by the combination of Vorapaxar and Fedratinib.	Myeloproliferative neoplasm [2A20]	[35]
MK-4827	DMLYGH4	Moderate	Increased risk of bleeding by the combination of Vorapaxar and MK-4827.	Ovarian cancer [2C73]	[42]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Vorapaxar caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[46]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Vorapaxar caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[47]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Vorapaxar caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[42]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Vorapaxar caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[36]
Curcumin	DMQPH29	Minor	Increased risk of bleeding by the combination of Vorapaxar and Curcumin.	Solid tumour/cancer [2A00-2F9Z]	[48]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Vorapaxar caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[49]
Betrixaban	DM2C4RF	Major	Increased risk of bleeding by the combination of Vorapaxar and Betrixaban.	Venous thromboembolism [BD72]	[35]
-----------


⏷ Show the Full List of 25 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Carmellose sodium	E00625	Not Available	Disintegrant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Hypromellose	E00634	Not Available	Coating agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Cellulose microcrystalline	E00698	Not Available	Adsorbent; Suspending agent; Diluent
--------------------


⏷ Show the Full List of 9 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Vorapaxar Sulfate eq 2.08mg base tablet	eq 2.08mg base	Tablet	Oral
Vorapaxar 2.08 mg tablet	2.08 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4047).
2	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
7	In Process Citation. Pharm Unserer Zeit. 2009;38(4):320-8.
8	Novel antiplatelet strategies in acute coronary syndromes. Cleve Clin J Med. 2009 Apr;76 Suppl 1:S8-15.
9	Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009 Mar 14;373(9667):919-28.
10	Vorapaxar: the missing link in antiplatelet therapy! J Anaesthesiol Clin Pharmacol. 2017 Apr-Jun;33(2):269-270.
11	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
20	Riociguat (adempas): a novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P T. 2014 Nov;39(11):749-58.
21	Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85.
22	Characterization of rat and human CYP2J enzymes as Vitamin D 25-hydroxylases. Steroids. 2006 Oct;71(10):849-56.
23	Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity. Drug Metab Dispos. 2012 May;40(5):943-51.
24	Inhibitory effects of antihypertensive drugs on human cytochrome P450 2J2 activity: Potent inhibition by azelnidipine and manidipine. Chem Biol Interact. 2019 Jun 1;306:1-9.
25	Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab Dispos. 2006 Nov;34(11):1793-7.
26	Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.
27	Nonclinical pharmacokinetics and in vitro metabolism of H3B-6545, a novel selective ERalpha covalent antagonist (SERCA). Cancer Chemother Pharmacol. 2019 Jan;83(1):151-160.
28	Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin-Acute Coronary Syndromes Trial. Circulation. 2011 May 3;123(17):1843-53.
29	PAR1 (Protease-Activated Receptor 1) Pepducin Therapy Targeting Myocardial Necrosis in Coronary Artery Disease and Acute Coronary Syndrome Patients Undergoing Cardiac Catheterization: A Randomized, Placebo-Controlled, Phase 2 Study. Arterioscler Thromb Vasc Biol. 2020 Dec;40(12):2990-3003.
30	RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc Drug Rev. 2003 Winter;21(4):313-26.
31	In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist. Eur J Pharmacol. 1999 Nov 19;384(2-3):197-202.
32	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 347).
33	Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12257-62.
34	Himbacine derived thrombin receptor (PAR-1) antagonists: SAR of the pyridine ring. Bioorg Med Chem Lett. 2007 Aug 15;17(16):4509-13.
35	Product Information. Zontivity (vorapaxar). Merck & Company Inc, Whitehouse Station, NJ.
36	Cerner Multum, Inc. "Australian Product Information.".
37	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
38	Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
39	Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
40	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
41	Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
42	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
43	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
44	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
45	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
46	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
47	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
48	Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
49	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.